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A B S T R A C T
In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological
processes that may be aberrant in schizophrenia. However, more information regarding psychometric properties and correlations with standard neuropsychological
tests and functional measures is warranted to establish their validity as treatment outcome measures. The N-back and AX-Continuous Performance Task (AX-CPT) are
two promising cognitive neuroscience tests designed to measure specific components of working memory and contextual processing respectively. In the current
study, we report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological
measures and functional capacity measures. The results suggest that while the AX-CPT and N-back display favorable psychometric properties, they do not exhibit
greater sensitivity or specificity with functional measures than standard neurocognitive tests.
1. Introduction
Cognitive impairments are a core feature of schizophrenia and a
major determinant of poor functional outcome (Green, 1996; Harvey
et al., 1998). Over the past decade interest has grown in treating cog-
nitive impairments through cognitive remediation (Best and Bowie,
2017; Kurtz et al., 2007; McGurk et al., 2007; Medalia et al., 2000;
Vinogradov, 2019), aerobic exercise (Firth et al., 2017; Kimhy et al.,
2015), and pharmacologic approaches (Davidson and Keefe, 1995;
Hyman and Fenton, 2003). As part of the Measurement and Treatment
Research to Improve Cognition in Schizophrenia (MATRICS) initiative,
the MATRICS Consensus Cognitive Battery (MCCB) was developed for
assessing cognitive change in clinical treatment studies. In choosing the
tests for the MCCB, an emphasis was placed on their psychometric
properties, standardization and ease of administration for multi-site
clinical trials (Nuechterlein et al., 2008) and thus most of the ten tests
eventually chosen were selected from existing standard neuropsycho-
logical (NP) tests. However, because of the history of clinical NP test
development, with a focus on broad sensitivity to impairment, the
standard NP tests chosen for the MCCB are likely to be limited in their
sensitivity to specific cognitive functions mediated by discrete neuro-
biological processes.
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Cognitive neuroscience methods with known linkages to specific
brain systems provide a logical alternative or supplementary assess-
ment strategy for identifying specific cognitive impairments to be tar-
geted in schizophrenia treatment trials. However, their utility in a
multi-site clinical trial remains unproven.
Two promising cognitive neuroscience tasks, the AX-Continuous
Performance Task (AX-CPT) and the N-back, were designed to measure
specific components of working memory and contextual processing.
The AX-CPT measures contextual processing, i.e., the ability to main-
tain a representation of context in order to mediate an appropriate
behavioral response (ServanSchreiber et al., 1996). In the AX-CPT, a
series of letters are presented to the subject who is instructed to hit a
“target” button only when they see an “X” that was immediately pre-
ceeded by an “A”. A meta-analysis of behavioral studies using the AX-
CPT and its nonverbal analog, the Dot Pattern Expectancy Task (DPX),
demonstrated a specific deficit in contextual processing in patients with
schizophrenia and groups at risk for schizophrenia-spectrum psycho-
pathology (Chun et al., in press). The N-back is a working memory test
in which letters are presented sequentially and participants indicate
whether the current stimulus matches the letter presented a specified
interval back (Cohen et al., 1997). A meta-analysis of functional neu-
roimaging studies found that during N-back performance, patients with
schizophrenia showed both hypo- and hyper-activation in specific re-
gions theoretically implicated in working memory processes (Glahn
et al., 2005).
The current study, Treatment Units for Research on Neurocognition
and Schizophrenia (TURNS) Merck (MK)-0777, employed the N-back
and AX-CPT. These tasks were chosen because a pilot study found
beneficial effects of the compound on performance of these two tests
(Lewis et al., 2008). Both of these tasks have shown promise in char-
acterizing the cognitive deficits associated with schizophrenia. How-
ever, questions remain regarding the utility of these tests in a clinical
trial setting. The psychometric characteristics of the N-back have been
relatively poorly examined in comparison with those of the AX-CPT,
and the psychometric properties of neither test have been characterized
in a multi-site treatment study. Additionally only a handful of studies
have assessed the relationships between these tasks and aspects of
functional outcome such as performance in clinical NP tests and func-
tional capacity measures. Those studies have presented mixed findings:
several AX-CPT studies found that overall sensitivity to context (d-
prime-context index) predicted performance-based and informant-rated
measures of functioning but had no association with clinician-rated or
self-reported levels of functioning (Gold et al., 2012; Owoso et al.,
2013; Sheffield et al., 2014). The N-back has shown associations with
performance-based measures of financial, communication, and total
functioning, as well as clinician-rated measures of occupational func-
tioning following intensive cognitive training (Lees et al., 2015;
Subramaniam et al., 2014). Overall, however, the relationship of the
AX-CPT and N-back with functional capacity remains unclear, and may
depend on which functional measures are used. In sum, the literature to
date has primarily examined the correlates of these measures in non-
treatment studies but their utility in large-scale treatment outcome
trials has not yet been firmly established.
Before these tests are likely to be widely adopted as treatment
outcome measures, they must demonstrate utility in multi-site treat-
ment trials. In the current manuscript, we analyze data collected during
the course of a multi-site treatment study to characterize the psycho-
metric properties of the AX-CPT and N-back as well as the relationship
of performance on these two tests to performance on a battery of
standard neuropsychological tests (the MCCB) and measures of func-
tional capacity (Schizophrenia Cognition Rating Scale (SCoRS) (Keefe
et al., 2006) and UCSD Performance-Based Skills Assessment (UPSA)
(Patterson et al., 2001)). We report here that the AX-CPT and N-back
did not demonstrate superior psychometric properties or stronger as-
sociations with functional capacity in comparison to standard neu-
ropsychological measures.
2. Materials and methods
2.1. Subjects
Six of the seven NIMH TURNS network sites implemented the 4-
week, placebo-controlled, parallel group, double-blind study, with the
primary purpose of testing the effect of adjunctive MK-0777 adminis-
tration on cognition in individuals with schizophrenia. Inpatients or
outpatients aged 18 to 60, who met DSM-IV-TR criteria for schizo-
phrenia, were selected for study entry. Participants were diagnosed
based on information from the Structured Clinical Interview for DSM-IV
(First et al., 1997), direct assessment, family informants, and past
medical records. Participants were required to be clinically stable, in
the non-acute phase of their illness, and to meet the following inclusion
criteria (Buchanan et al., 2005): a) treatment with no more than two
second generation antipsychotic medications, other than clozapine, for
the previous two months, with no dose change in the month prior to
study entry; b) Brief Psychiatric Rating Scale (BPRS) (Overall and
Gorham, 1962) hallucinatory behavior and unusual thought content
item scores ≤5; c) BPRS conceptual disorganization item ≤4; d)
Simpson-Angus Scale (Hawley et al., 2003) total score≤ 6; and e)
Calgary Depression Scale (Addington et al., 1990) total score≤ 10
(Buchanan et al., 2005; Buchanan et al., 2011b).
Participants were required to: 1) validly complete the MCCB (Kern
et al., 2008; Nuechterlein et al., 2008); 2) to score at least one standard
deviation (SD) below absolute maximum on one or more of the fol-
lowing tests: Letter-Number Span; Hopkins Verbal Learning Test, and
Identical Pairs Continuous Performance Test (CPT-IP) as a means to
avoid ceiling effects; and 3) have a Wechsler Test of Adult Reading
(Wechsler, 2001) raw score≥ 6.
Participants were excluded if they had a DSM-IV diagnosis of al-
cohol or substance abuse (other than nicotine) within the last month,
alcohol or substance dependence (other than nicotine) within the last
6 months, or mental retardation; had a history of significant head in-
jury/trauma or clinically significant medical or neurological disease;
were treated with drugs known to act at the GABAA receptor or to in-
hibit CYP3A4; had a history of severe benzodiazepine withdrawal;
participated in a clinical trial of investigational medication within
60 days; or a history of posterior subcapsular cataracts or age-incon-
sistent nuclear or cortical cataracts, or uveitis. Women of childbearing
age were included if using adequate birth control.
The participating institution IRBs approved the study protocol and
informed consent procedures. Written informed consent was obtained
from all participants after study procedures had been fully explained
and prior to study participation. Participant ability to provide valid
informed consent was documented using study specific procedures.
2.2. Assessments
Cognition was assessed with both the MCCB (Nuechterlein et al.,
2008) and with the SCoRS (Keefe et al., 2006). The UPSA-2 (Patterson
et al., 2001), was used to assess functional capacity.
In addition to the MCCB and SCoRS, cognition was assessed by two
tests that have been found to activate prefrontal cortical function, the
AX-CPT (Cohen et al., 1999) and N-back (Cohen et al., 1997), as a pilot
study found that patients receiving MK-077 showed improvement on
these measures (Lewis et al., 2008). Of note, this version of the AX-CPT
did not include any of the optimizations or administration improve-
ments reported in Henderson et al. (Henderson et al., 2012). Stimuli
were white, 60 point Arial letters on a black background. Subjects re-
sponded by pressing one of two buttons on a response pad: left button
for non-targets and right button for targets. Stimuli were comprised of a
series of letters explicitly grouped into cue-probe pairings by under-
lining of the cue letters. Subjects were instructed to respond to each
letter as quickly as possible. Targets were defined as an X that is im-
mediately preceded by an A (AX trials). A letter in any other sequence
M.S. Kraus, et al. Schizophrenia Research: Cognition 19 (2020) 100161
2
was defined as a non-target (AY, BX and BY trials, where “B” represents
any non-A cue and “Y” represents any non-X probe). Both cues and
probes were presented for 500ms. The delay between the cue and the
probe was 5500ms, while the inter-trial interval was 1500ms. The test
consisted of four blocks of trials, each composed of: 30 AX trials
(78.9%), 3 AY trials (7.9%), 3 BX trials (7.9%) and 2 BY trials (5.3%).
This trial type distribution produces a high expectation of an X probe
following the presentation of an A cue. Intact use of this expectation is
associated with a high rate of AY errors (and slow responding on correct
AY trials), while impaired use of the context provided by the A or not-A
cue is associated with increased false alarms on BX trials.
The N-back is a working memory test in which memory load is
manipulated by changing the size of the interval across blocks. In this
study, 0-back, 1-back, and 2-back condition were presented, in that
order. In the 0-back condition, the subject was asked to press the
“target” button upon the presentation of a pre-specified target letter
(“Z”). In the 1-back condition, the subject was asked to press the
“target” button to the second of two consecutive, identical letters. In the
2-back condition, the subject was asked to press the “target” button if a
letter was identical to that presented two trials earlier. In all conditions,
letters were presented for 500ms with a 2000ms delay between the end
of one letter presentation and the beginning of the next. In addition to
target trials (33.3% of trials), non-target trials consisted of repeated
distractor trials (16.65% of trials) in which the current letter was a
repeat of a letter near the target interval (e.g., 1 or 3 letters back during
the 2-back condition) and novel trials (50% of trials) in which letters
were not repeated within the “repeated distractor” window.
2.3. Study design
Participants who met inclusion criteria entered a 2-week placebo
lead-in Evaluation Phase during which they underwent baseline cog-
nitive, functional capacity, symptom and safety assessments.
Participants who continued to meet inclusion criteria entered the 4-
week, double-blind Treatment Phase and were randomized to MK-0777
3mg BID; MK-0777 8mg BID; or placebo BID. At week 4 of the
Treatment Phase, patients received repeat administration of cognitive,
functional capacity, symptom and safety assessments. The treatment
data have been presented in a previous manuscript (Buchanan et al.,
2011a).
2.4. Data quality review
Throughout the trial, all neurocognitive data were reviewed to en-
sure adherence to testing protocols and to assess test validity. This
process was particularly relevant to the AX-CPT and N-back tests as
several unique issues, including failure to understand the task instruc-
tions, inattentiveness to the test and equipment problems, could im-
pinge upon the collection of valid data in these tests. For the AX-CPT
and N-back, final decisions regarding data validity were agreed upon by
a core of neuropsychologists (Deanna Barch, Jim Gold and Mike Kraus)
most experienced with these tests. All decisions were made blind to
subject group and time point. Although decisions were made based on
the whole picture the data presented and considering notes left by the
tester regarding the sessions in question, the group agreed on some
general guidelines. AX-CPT tests were flagged for review if any of the
following were true: the participant failed to respond to 20% or more of
trials, missed all BX trials, missed> 25% of BY trials or failed to score
significantly above chance on AX trials. N-back tests were flagged for
review if any of the following were true: the participant failed to re-
spond to 20% or more of trials, the subject missed all repeat distractor
trials or answered very few target trials correctly (this last criterion
varied across conditions). Because the N-back was divided into 0, 1 and
2-back blocks, decisions on test validity were made on a block-by-block
basis.
2.5. Statistical analyses
For the AX-CPT and N-back tests, the loglinear method was used to
calculate d-prime (Stanislaw and Todorov, 1999). For the AX-CPT, only
BX trials were used to calculate the false alarm rate, thus establishing a
“d-prime-context” score (Cohen et al., 1999). Although we designed the
AX-CPT with a low percentage of BX trials to produce a high expecta-
tion of AX target trials, we had sufficient variance on BX trials to pro-
duce a valid d-prime measure. For the N-back, trials with novel and
repeated distractors were pooled in calculating the false alarm rate.
As previously reported (Buchanan et al., 2011b), treatment in this
study had no significant effect beyond placebo on any measure, and all
treatment groups had very similar mean scores and SDs (SD). Therefore,
all analyses were completed from data pooled across all three treatment
groups. The test-retest reliabilities of the AX-CPT and N-back outcome
variables were calculated as intra-class correlation coefficients using
the REML method with SAS PROC VARCOMP. Week, treatment, and
treatment x week were treated as fixed effects in the variance compo-
nent model, to remove systematic practice or drug effects from esti-
mates of random within-subject error. Learning effects were in-
vestigated by calculation of Cohen's d (mean change/SD change) and
the statistical significance of these effects was assessed using paired t-
tests. Floor and ceiling effects were calculated as the percentage of
subjects within one SD (estimated as the square root of the sum of
between- and within-subjects variance components using SAS PROC
Varcomp) of worst possible performance and perfect performance re-
spectively. Similarly, we also calculated the percentage of subjects
“near chance” as those within one SD from chance performance.
Pearson correlation coefficients were calculated to investigate the re-
lationships at baseline across all subjects of AX-CPT and N-back out-
comes with standard neurocognitive measures, an interview-based
measure of cognition, functional capacity and symptom measures.
3. Results
3.1. Subject numbers, demographics and missing data rates
54 subjects completed the overall study. However, 2 of these did not
complete the AX-CPT or N-back at either time point. Thus the subject
pool for this study consisted of 52 patients who completed AX-CPT and
N-back. Baseline characteristics of this sample are presented in Table 1.
Of the 104 AX-CPT tests across both time points, 6 (5.77%) were
deemed invalid. Of the 104 N-back tests, 1 (0.96%) was judged to have
invalid 1-back conditions and 1 (0.96%) was judged to have invalid 2-
back conditions.
3.2. Psychometric properties
Of all the AX-CPT variables, the highest reliability was found for d-
prime (0.72), while the ICCs of individual trial types were lower (0.37
to 0.64) (see Table 2). N-back d-prime reliability was considerably
better for 1-back (0.66) and 2-back (0.62) than for 0-back (0.40).
Learning effects were investigated by calculating Cohen's d. Of all the
AX-CPT and N-back variables, only the 2-back d-prime exhibited a
significant learning effect (Cohen's d=0.55, p= .05). Of the 2-back
reaction time measures, target hit and repeat correct rejection reaction
times demonstrated similar reliability to the 2-back d-prime measure,
while the novel correct rejection reaction time reliability was very low.
None of the 2-back reaction time measures exhibited a learning effect.
Because no effect of treatment was found, the analysis of floor and
ceiling effects was completed in the entire sample. These measures were
calculated using all completed tests regardless of their judged validity,
thus allowing an accurate assessment of patients scoring near floor and
chance levels. The AX-CPT exhibited a substantial ceiling effect at both
baseline (23.3% of d-prime-context scores were within 1 SD of the
maximum possible score) and four weeks (26.9%) (Table 3).
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Additionally, a fairly large percentage of subjects scored near chance at
both baseline (23.3%) and four weeks (30.8%). Ceiling effects for the N-
back varied across conditions, as expected, with a large percentage of
subjects within 1 SD of ceiling on the 0-back (47.5% at baseline, 50.9%
at 4 weeks), a small percentage on the 1-back (13.1% at baseline, 13.2%
at 4 weeks) and none on the 2-back. Subjects only performed within 1
SD of chance on the 1-back at baseline (1.6%) and the 2-back (16.4% at
baseline, 9.4% at 4 weeks). No floor effects were found for either task.
Reliability was stronger for AX-CPT critical (BX) trials and overall
sensitivity to context than for other trials. N-back trials requiring
working memory (1-back and 2-back) showed greater reliability than
those primarily tapping sustained attention (0-back); however, none of
these d-prime variables achieved the minimum level of reliability of the
CNTRICS criteria (ICC= 0.70) (Barch et al., 2008). Learning effects
were minimal.
3.3. Relationships to other cognitive domains
For the AX-CPT, d-prime-context showed significant positive cor-
relations with all cognitive domain and test scores from the MCCB
(Table 4). The strongest correlations were with the domains of pro-
cessing speed (0.57), visual memory (0.50) working memory (0.44) and
attention/vigilance (0.42). AX and BX accuracy showed similar—but
slightly weaker—correlations with MCCB variables.
Of the N-back variables, the 2-back d-prime correlated most
strongly and consistently with cognitive outcomes (Table 4), only
failing to be statistically significant for social cognition. The 1-back d-
prime also correlated with most cognitive measures, only failing to be
statistically significant for T-scores in the domains of social cognition
and reasoning/problem solving and the test of category fluency. The 0-
back d-prime was less strongly correlated with cognitive variables, and
was only statistically significant for verbal memory and visual memory.
2-back reaction time variables (Supplementary Table 1) exhibited far
fewer significant correlations with cognitive variables than did 2-back
d-prime. In sum, the AX-CPT and working memory trials of the N-back
were associated with most cognitive variables on the MCCB, thereby
demonstrating convergent validity.
3.4. Relationship to UPSA and SCoRS
The AX-CPT d-prime-context showed significant positive correla-
tions with UPSA summary and subscale scores, but was not correlated
with the SCoRS global interviewer score (Table 5). Of the N-back
variables, 2-back d-prime was most strongly correlated with UPSA
variables, with all but Comprehension/Planning being statistically sig-
nificant (Table 5). By means of comparison, the CPT-IP from the MCCB
only correlated significantly with the Comprehension/Planning
(r=0.31, p < .05) and Financial (r=0.32, p < .05) domains of the
UPSA. 2-back reaction times were not as consistently correlated with
UPSA scores as was 2-back d-prime. The 1-back d-prime was positively
correlated with the UPSA summary score, but none of the correlations
with the UPSA subscales reached significance. The 0-back was not
significantly correlated with any functional outcomes. No N-back con-
ditions were correlated with SCoRS. In sum, the AX-CPT and working
memory trials of the N-back were associated with overall functioning
on the UPSA but neither set of tasks was related to functioning on the
SCoRS.
4. Discussion
The cognitive neuroscience measures investigated in this study are
more time-consuming and burdensome than standard neuropsycholo-
gical tests. To justify their inclusion in clinical trials, cognitive neu-
roscience tests must display better psychometric properties than stan-
dard neuropsychological tests, or more specificity with the effects of
cognitive treatment or with functional outcomes. We have not seen
Table 1
Baseline characteristics of study participants.
Characteristic %
Female gender 32.8
White 46.6
Black 39.7
Other 13.8
Hispanic 15.5
Married 10.3
Divorced/separated 22.4
Never married 67.2
Antipsychotics
Aripiprazole 31.5
Olanzapine 22.2
Quetiapine 11.1
Risperidone/Paliperidone 33.3
Ziprasidone 3.7
Polypharmacya 3.7
Characteristic Mean S.D.
Age, years 42.6 9.5
Education, years 13.3 2.8
WTAR score 29.5 11.9
BPRS total score 27.6 6.0
BPRS psychosis 6.9 3.1
SANS total score 18.7 12.5
CDRS total score 1.5 2.0
UPSA summary score 91.6 15.3
ScoRS interviewer global rating 4.4 2.3
a One patient each treated with aripiprazole plus olanzapine or aripiprazole
plus ziprasidone.
Table 2
AX-CPT and N-back reliability and learning effects.
Measure ICC Change over 4 weeks
Mean S.D. d t P-value
AX-CPT
D-prime 0.72 −0.03 1.06 −0.03 −0.11 0.92
AX hits (%) 0.37 3.47 15.15 0.26 0.89 0.39
AY correct rejections
(%)
0.50 −1.80 8.43 −0.21 −0.83 0.42
BX correct rejections
(%)
0.64 −4.93 26.29 −0.19 −0.73 0.48
N-back d-prime
0-Back (all distractors) 0.40 −0.04 0.49 −0.08 −0.32 0.76
1-Back (all distractors) 0.66 0.03 0.53 0.06 0.26 0.80
2-Back (all distractors) 0.62 0.23 0.45 0.55 2.15 0.05
2-Back correct response
times (RT)
Target hit RT 0.61 41.22 183.39 0.24 0.95 0.35
Novel correct rejection
RT
0.04 −135.94 440.80 −0.31 −1.31 0.21
Repeated correct
rejection RT
0.55 −20.39 228.22 −0.09 −0.38 0.71
Table 3
Floor and ceiling effects for AX-CPT and N-back measures.
Measure Week % Near
floor
% Near
chance
% Near ceiling
AX-CPT d-prime 0 0.0 23.3 23.3
4 0.0 30.8 26.9
N-back d-prime
0-back (all distractors) 0 0.0 0.0 47.5
4 0.0 0.0 50.9
1-back (all distractors) 0 0.0 1.6 13.1
4 0.0 0.0 13.2
2-back (all distractors) 0 0.0 16.4 0.0
4 0.0 9.4 0.0
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evidence for either of these criteria with the AX-CPT and N-back tests
employed in the current study.
Although the current study does not support the widespread adop-
tion of the AX-CPT or N-back in clinical trials, it does allow some
conclusions regarding which of the many outcome variables produced
by these tests are most promising. Identification of the most promising
variables for use in future clinical studies may help reduce the need to
correct for multiple comparisons and thereby reduce the likelihood of
Type II errors. Of the three N-back conditions, the 2-back d-prime
scores correlated most strongly with cognition and functional capacity.
The 2-back d-prime correlated most strongly with the cognitive domain
of working memory, consistent with its classification as a working
memory task, while the 1-back correlated with attention/vigilance
more strongly than did the 2-back. While other studies have used 2-
back reaction times as an outcome measure, our results suggest it is less
promising than the 2-back d-prime measure as it did not correlate
significantly with functional capacity or any neuropsychological do-
mains. Thus, of all the N-back variables investigated in this study, the 2-
back d-prime appears to have the best combination of construct va-
lidity, favorable psychometric properties and relation to functional
capacity.
The psychometric properties of the AX-CPT used in this study lar-
gely conform to the criteria of optimal cognitive neuroscience tasks as
described for CNTRICS (Barch et al., 2008), though this is not the
version developed and optimized as part of the CNTRAC consortium
(Henderson et al., 2012). The d-prime-context ICC in the current study
just meets the minimum criterion and is consistent with previous
reports of approximately 0.70. In contrast to Strauss and colleagues
(Strauss et al., 2014), but consistent with Barch and colleagues' (Barch
et al., 2003) findings, there was no evidence of an overall practice effect
for the AX-CPT in the current study. Single condition variables for the
test were likewise free from practice effects but exhibited much lower
reliability than d-prime-context, consistent with previous reports.
Perhaps the most concerning psychometric property exhibited by
the AX-CPT in this study was the appreciable ceiling effect for d-prime-
context scores at both baseline and 4weeks. The Dot Pattern
Expectancy (DPX) variant of the AX-CPT task, developed as part of the
CNTRACs consortium (Henderson et al., 2012), has fewer ceiling ef-
fects, many fewer subjects failing to complete the task due to clearer
instructions, more user friendly administration, and test-retest relia-
bility within the recommended range. Thus, this optimized DPX is likely
a better choice for use in clinical trials.
Although the current study addresses the feasibility and psycho-
metric properties of the AX-CPT and N-Back in a multi-site trial, we did
not observe an effect of the investigational drug (Buchanan et al.,
2011a). Thus we were unable to assess the sensitivity of these measures
to cognitive changes associated with effective drug treatment. Ad-
ditionally, the current study included assessments of functional capa-
city, but not direct measures of occupational or social functioning. It
will be important that future studies investigate the sensitivity of these
and other cognitive neuroscience based measures to cognitive change
and their relationship to functional outcomes.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scog.2019.100161.
Table 4
Baseline correlations of AX-CPT and N-back outcomes with MCCB.
MCCB Domain Score or Test AX-CPT N-back
d-Prime AX Hits AY reject BX reject 0-Back
(N=52)
1-Back
(N=52)
2-Back
(N=51)
Attention/vigiliance (CPT-IP) 0.42⁎⁎ 0.26 0.20 0.37⁎⁎ 0.22 0.51⁎⁎ 0.38⁎⁎
Processing speed 0.57⁎⁎ 0.54⁎⁎ 0.06 0.33⁎ 0.25 0.52⁎⁎ 0.60⁎⁎
BACS symbol coding 0.55⁎⁎ 0.50⁎⁎ −0.11 0.32⁎ 0.25 0.58⁎⁎ 0.57⁎⁎
Category fluency 0.42⁎⁎ 0.40⁎⁎ 0.19 0.25 0.25 0.24 0.37⁎⁎
Trails A 0.39⁎⁎ 0.40⁎⁎ 0.10 0.23 0.12 0.40⁎⁎ 0.48⁎⁎
Reasoning/problem solving (NAB mazes) 0.27 0.28 −0.05 0.18 0.07 0.27 0.29⁎
Social cognition (MSCEIT managing emotions) 0.32⁎ 0.27 −0.15 0.15 0.10 0.11 0.13
Verbal memory (Hopkins verbal learning test-R) 0.35⁎ 0.26 0.10 0.15 0.33⁎ 0.38⁎⁎ 0.61⁎⁎
Visual memory (Brief visuospatial memory test) 0.50⁎⁎ 0.32⁎ 0.03 0.33⁎ 0.38⁎⁎ 0.46⁎⁎ 0.39⁎⁎
Working memory 0.44⁎⁎ 0.40⁎⁎ 0.03 0.29⁎ 0.13 0.45⁎⁎ 0.67⁎⁎
Letter number sequencing 0.44⁎⁎ 0.47⁎⁎ 0.04 0.24 0.07 0.34⁎ 0.57⁎⁎
WMS III spatial span 0.31⁎ 0.21 0.02 0.27 0.17 0.43⁎⁎ 0.56⁎⁎
Overall composite 0.61⁎⁎ 0.49⁎⁎ 0.09 0.39⁎⁎ 0.31⁎ 0.55⁎⁎ 0.60⁎⁎
⁎ p < .05.
⁎⁎ p < .01.
Table 5
Baseline correlations of AX-CPT and N-back outcomes with SCoRS and UPSA.
AX-CPT d-prime
N=46
0-Back d-prime
N=52
1-Back d-prime
N=52
2-Back d-prime
N=51
2-Back target RT 2-Back novel distractor RT 2-Back repeat distractor RT
SCRS Int Global 0.04 0.09 −0.05 −0.17 0.00 0.00 −0.11
UPSA summary 0.57⁎⁎ 0.08 0.29⁎ 0.56⁎⁎ 0.21 0.05 0.42⁎⁎
Comp/planning 0.34⁎ 0.03 0.05 0.27 −0.04 0.12 0.20
Financial 0.40⁎⁎ 0.11 0.35 0.45⁎⁎ 0.11 −0.08 0.43⁎⁎
Communication 0.54⁎⁎ 0.19 0.31 0.52⁎⁎ 0.06 0.13 0.34⁎
Transportation 0.41⁎⁎ −0.02 0.22 0.32⁎ 0.11 −0.12 0.17
Household 0.35⁎ 0.07 0.11 0.35⁎ 0.32⁎ 0.01 0.39⁎⁎
Medication 0.37⁎⁎ −0.06 0.26 0.48⁎⁎ 0.29⁎ 0.14 0.24
RT= response time, SCoRS Global= SCoRS interviewer global score, UPSA Summary=UPSA total summary score, Orgplan=UPSA organization and planning
subscale, Financial=UPSA financial skills subscale, Communication=UPSA communication subscale, Tranportation=UPSA transportation subscale,
Household=UPSA household management subscale, Medication=UPSA medication management subscale.
⁎ p < .05.
⁎⁎ p < .01.
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